A safe procedure for transporting bone-marrow for purging in a central laboratory

Area of Science:

• Pediatric Oncology
• Hematology
• Immunology

Background:

• Neuroblastoma treatment often involves autologous bone marrow transplantation.
• Ex vivo purging of neuroblastoma cells from bone marrow is crucial for successful transplantation.
• Centralized processing facilities can streamline this complex procedure.

Purpose of the Study:

• To compare patient outcomes (survival time and engraftment rate) using bone marrow processed locally versus bone marrow shipped from other centers.
• To evaluate the efficacy of a central facility for ex vivo neuroblastoma cell removal.

Main Methods:

• A comparative study involving 164 evaluable pediatric oncology patients.
• Bone marrow harvested either at the University of Florida (UF) or participating Pediatric Oncology Group (POG) centers.
• Ex vivo purging of neuroblastoma cells using an immunomagnetic technique for transported marrow.

Main Results:

• No statistically significant differences were observed in survival time (p=0.2463) between the two groups.
• Similarly, no significant differences were found in the rate of bone marrow engraftment (p=0.3259).
• The study included 169 patients, with 164 evaluable (29 UF, 135 transported).

Conclusions:

• Transporting bone marrow for ex vivo purging does not negatively impact patient survival or engraftment rates.
• A central processing facility is a viable option for neuroblastoma treatment, ensuring comparable outcomes to local processing.
• This validates the effectiveness of the immunomagnetic purging technique regardless of marrow origin.